Literature DB >> 22569827

Oestrogen-induced genes in ductal carcinoma in situ: their comparison with invasive ductal carcinoma.

Akiko Ebata1, Takashi Suzuki, Kiyoshi Takagi, Yasuhiro Miki, Yoshiaki Onodera, Yasuhiro Nakamura, Fumiyoshi Fujishima, Kazuyuki Ishida, Mika Watanabe, Kentaro Tamaki, Takanori Ishida, Noriaki Ohuchi, Hironobu Sasano.   

Abstract

It is well known that oestrogens play important roles in both the pathogenesis and development of invasive ductal carcinoma (IDC) of human breast. However, molecular features of oestrogen actions have remained largely unclear in pure ductal carcinoma in situ (pDCIS), regarded as a precursor lesion of many IDCs. This is partly due to the fact that gene expression profiles of oestrogen-responsive genes have not been examined in pDCIS. Therefore, we first examined the profiles of oestrogen-induced genes in oestrogen receptor (ER)-positive pDCIS and DCIS (DCIS component (DCIS-c)) and IDC (IDC component (IDC-c)) components of IDC cases (n=4 respectively) by microarray analysis. Oestrogen-induced genes identified in this study were tentatively classified into three different groups in the hierarchical clustering analysis, and 33% of the genes were predominantly expressed in pDCIS rather than DCIS-c or IDC-c cases. Among these genes, the status of MYB (C-MYB), RBBP7 (RBAP46) and BIRC5 (survivin) expressions in carcinoma cells was significantly higher in ER-positive pDCIS (n=53) than that in ER-positive DCIS-c (n=27) or IDC-c (n=27) by subsequent immunohistochemical analysis of the corresponding genes (P<0.0001, P=0.03 and P=0.0003 respectively). In particular, the status of C-MYB immunoreactivity was inversely (P=0.006) correlated with Ki67 in the pDCIS cases. These results suggest that expression profiles of oestrogen-induced genes in pDCIS may be different from those in IDC; and C-MYB, RBAP46 and survivin may play important roles particularly among oestrogen-induced genes in ER-positive pDCIS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22569827     DOI: 10.1530/ERC-11-0345

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  6 in total

1.  Altered genome-wide methylation in endometriosis.

Authors:  Hanyia Naqvi; Ysabel Ilagan; Graciela Krikun; Hugh S Taylor
Journal:  Reprod Sci       Date:  2014-04-30       Impact factor: 3.060

2.  Bioinformatics Analysis Highlight Differentially Expressed CCNB1 and PLK1 Genes as Potential Anti-Breast Cancer Drug Targets and Prognostic Markers.

Authors:  Leiming Fang; Qi Liu; Hongtu Cui; Yunji Zheng; Chengjun Wu
Journal:  Genes (Basel)       Date:  2022-04-07       Impact factor: 4.141

3.  Intratumoral estrogen concentration and expression of estrogen-induced genes in male breast carcinoma: comparison with female breast carcinoma.

Authors:  Kiyoshi Takagi; Takuya Moriya; Masafumi Kurosumi; Kimako Oka; Yasuhiro Miki; Akiko Ebata; Takashi Toshima; Shoji Tsunekawa; Hiroyuki Takei; Hisashi Hirakawa; Takanori Ishida; Shin-Ichi Hayashi; Junichi Kurebayashi; Hironobu Sasano; Takashi Suzuki
Journal:  Horm Cancer       Date:  2012-10-18       Impact factor: 3.869

4.  BUB1 immunolocalization in breast carcinoma: its nuclear localization as a potent prognostic factor of the patients.

Authors:  Kiyoshi Takagi; Yasuhiro Miki; Yukiko Shibahara; Yasuhiro Nakamura; Akiko Ebata; Mika Watanabe; Takanori Ishida; Hironobu Sasano; Takashi Suzuki
Journal:  Horm Cancer       Date:  2013-01-04       Impact factor: 3.869

5.  Cytochrome c1 in ductal carcinoma in situ of breast associated with proliferation and comedo necrosis.

Authors:  Mayuko Chishiki; Kiyoshi Takagi; Ai Sato; Yasuhiro Miki; Yuta Yamamoto; Akiko Ebata; Yukiko Shibahara; Mika Watanabe; Takanori Ishida; Hironobu Sasano; Takashi Suzuki
Journal:  Cancer Sci       Date:  2017-05-19       Impact factor: 6.716

6.  Intratumoral concentration of estrogens and clinicopathological changes in ductal carcinoma in situ following aromatase inhibitor letrozole treatment.

Authors:  K Takagi; T Ishida; Y Miki; H Hirakawa; Y Kakugawa; G Amano; A Ebata; N Mori; Y Nakamura; M Watanabe; M Amari; N Ohuchi; H Sasano; T Suzuki
Journal:  Br J Cancer       Date:  2013-06-11       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.